In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Therapeutic genome editing using CRISPR/Cas9 for arrhythmogenic cardiomyopathy induced pluripotent stem cells derived cardiac tissues

Session HFA Discoveries - ePublications

Speaker Oren Caspi

Event : HFA Discoveries 2020

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Diseases: Cardiomyopathies
  • Session type : ePublication

Authors : O Caspi (Haifa,IL), S Chrona (Haifa,IL), A Gepstein (Haifa,IL), A Shiti (Haifa,IL), I Huber (Haifa,IL), G Arbel (Haifa,IL), L Gepstein (Haifa,IL)

Authors:
O Caspi1 , S Chrona2 , A Gepstein2 , A Shiti2 , I Huber1 , G Arbel2 , L Gepstein1 , 1Rambam Health Care Campus, Cardiology - Haifa - Israel , 2Technion - Israel Institute of Technology - Haifa - Israel ,

Citation:

Introduction: CRISPR/Cas9 provides a novel methodology for selective gene editing. Application of genome editing for cardiomyopathies has been recently suggested as a potential therapeutic intervention. In the current study, we examine the ability of combined CRISPR/Cas9 and homologous recombination to serve as a therapeutic intervention for arrhythmogenic cardiomyopathy (AC).

Methods: Patient-specific-hiPSCs were generated from AC patient carrying a pathogenic mutation in PKP2. Patient’s hiPSC mutation was genetically corrected by using CRISPR/Cas9-based mutation correction and homologous recombination. The corrected cells served as isogenic-controls for the AC-hiPSCs. Real-time-PCR and Western-Blot analysis were used to assess for the molecular signature of the disease. Structural abnormalities were evaluated by immunostainings for desmosomal proteins and lipid-droplet accumulation. Patch-Clamp was used to assess INa current-kinetics at the cellular level. Conduction abnormalities and arrhythmogenesis using an electrophysiology study in a dish (EPS-in-a-dish) were evaluated at the tissue level using multilayered confluent hiPSC-derived cardiac cell tissues with optical mapping.

Results: CRISPR/Cas9 corrected hiPSCs demonstrated appropriate stem cell characteristics and differentiated to cardiomyocytes expressing typical molecular markers. The corrected-hiPSC expressed normal mRNA and protein levels of PKP2 based on real-time PCR and western-blots /immunofluorescence, respectively. Lipid droplet accumulation was significantly reduced in the corrected-hiPSCs when compared to AC-hiPSCs and was at similar levels to that of healthy-control-hiPSCs. Optical mapping revealed a significant increase in conduction velocity in the corrected-hiPSCs 61±2 cm/s compared with AC-hiPSCs 33±0.6cm/s (p<0.001) and was similar to that of control cells. The improved conduction velocity was associated with improved expression of Cx-43 and improved kinetics of INa in patch-clamp studies. Finally, the corrected-hiPSCs demonstrated decreased vulnerability for developing arrhythmia using EPS-in-a-dish study when compared to AC-hiPSCs.

Conclusion: CRISPR/Cas9 based therapeutic genome editing results in the restoration of functional and structural abnormalities associated with arrhythmogenic cardiomyopathy and may serve as a potential therapeutic intervention for genetic cardiomyopathies.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are